Table 4.
Treatment received by mHSPC patients immediately prior to being diagnosed with mCRPCa, overall, in EUR, and by country
| Total (n = 1131) | EUR (n = 1005) | France (n = 267) | Germany (n = 223) | Italy (n = 217) | Spain (n = 126) | UK (n = 172) | Japan (n = 126) | |
|---|---|---|---|---|---|---|---|---|
| ADT alone, n (%) | ||||||||
| Total | 839 (74) | 733 (73) | 225 (84) | 148 (66) | 166 (76) | 81 (64) | 113 (66) | 106 (84) |
| Chemotherapyb, n (%) | ||||||||
| Total | 147 (13) | 145 (14) | 14 (5) | 41 (18) | 25 (12) | 23 (18) | 42 (24) | 2 (2) |
| Docetaxel | 137 (12) | 137 (14) | 12 (4) | 40 (18) | 23 (11) | 21 (17) | 41 (24) | 0 (0) |
| Cabazitaxel | 6 (1) | 6 (1) | 0 (0) | 1 (< 1) | 2 (1) | 2 (2) | 1 (1) | 0 (0) |
| NHA, n (%) | ||||||||
| Total | 142 (13) | 125 (12) | 28 (10) | 32 (14) | 26 (12) | 22 (17) | 17 (10) | 17 (13) |
| Abiraterone | 99 (9) | 86 (9) | 19 (7) | 22 (10) | 18 (8) | 18 (14) | 9 (5) | 13 (10) |
| Enzalutamide | 34 (3) | 31 (3) | 9 (3) | 2 (1) | 8 (4) | 4 (3) | 8 (5) | 3 (2) |
| Apalutamide | 9 (1) | 8 (1) | 0 (0) | 8 (4) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
Treatments are ± ADT, unless otherwise stated
ADT androgen deprivation therapy, mCRPC metastatic castration-resistant prostate cancer, mHSPC metastatic hormone sensitive prostate cancer, NHA novel hormonal agent, UK United Kingdom
aOther treatment combinations including NHA and any other treatment combinations were both being used in 0.1% of patients overall
bChemotherapy other than docetaxel or cabazitaxel was being used in 0.3% of patients overall